Clinical trial
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
NCT04874350 is registered in ClinicalTrials.gov with Lipocine Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
- Lead sponsor
- Lipocine Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2021
- Completion date
- December 18, 2023
- Enrollment
- 30 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.